Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update | Lao Tribune

Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome –

– Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke –

Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease –